Baramidze A et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial. Lung Cancer 2024;193:107821. Abstract
Barlesi F et al. Adagrasib (ADA) vs docetaxel (DOCE) in patients (pts) with KRASG12C-mutated advanced NSCLC and baseline brain metastases (BM): Results from KRYSTAL-12. ESMO 2024;Abstract LBA57.
Cascone T et al. Neocoast-2: Efficacy and safety of neoadjuvant durvalumab (D) + novel anticancer agents + CT and adjuvant D ± novel agents in resectable NSCLC. WCLC 2024;Abstract PL02.07.
Cheng Y et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med 2024;391(14):1313-27. Abstract
Drilon AE et al. Repotrectinib in tyrosine kinase inhibitor (TKI)-naïve patients (pts) with advanced ROS1 fusion-positive (ROS1+) NSCLC in the phase 1/2 TRIDENT-1 trial: Clinical update, treatment beyond progression and subsequent therapies. ASCO 2024;Abstract 8522.
Eaton MS-S et al. LUNAR-2: Pivotal, randomized, open-label study of tumor treating fields (TTFields, 150 kHz) concomitant with pembrolizumab and platinum based chemotherapy for the treatment of metastatic non-small cell lung cancer. ASCO 2024;Abstract TPS8665.
Fang W et al. Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study. ASCO 2024;Abstract 8502.
Forde PM et al. Perioperative vs neoadjuvant nivolumab for resectable NSCLC: Patient-level data analysis of CheckMate 77T vs CheckMate 816. WCLC 2024;Abstract PL02.08.
Frost N et al. Phase 3 Trofuse-007 study: Sacituzumab tirumotecan plus pembrolizumab vs pembrolizumab alone for NSCLC with PD-L1 TPS ≥50%. WCLC 2024;Abstract P4.11D.02.
Garassino MC et al. Normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-Lung 01. WCLC 2024;Abstract PL02.11.
Johnson ML et al. Intracranial response in patients (pts) with baseline (BL) brain metastases (BM) and extensive-stage (ES) small cell lung cancer (SCLC) treated with ifinatamab deruxtecan (I-DXd) in the IDeate-Lung01 study. ESMO 2024;Abstract 1787P.
Kilickap S et al. Cemiplimab monotherapy for first line advanced NSCLC patients with PD-L1 expression ≥50%: 5-y outcomes of EMPOWER-Lung 1. WCLC 2024;Abstract OA11.06.
Mok TSK et al. KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. ASCO 2024;Abstract LBA8509.
Provencio Pulla M et al. Perioperative nivolumab (NIVO) v placebo (PBO) in patients (pts) with resectable NSCLC: Clinical update from the phase III CheckMate 77T study. ESMO 2024;Abstract LBA50.
Rudin CM et al. Ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer (ES-SCLC): Interim analysis of Ideate-lung01. WCLC 2024;Abstract OA04.03.
Sands J et al. Datopotamab deruxtecan vs docetaxel in patients with non-small cell lung cancer: Final overall survival from TROPION-Lung01. WCLC 2024;Abstract OA08.03.
Spicer J et al. Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816. ASCO 2024;Abstract LBA8010.
Zhou C et al. Phase 3 study of ivonescimab (AK112) vs. pembrolizumab as first-line treatment for PD-L1-positive advanced NSCLC: Primary analysis of HARMONi-2. WCLC 2024;Abstract PL02.04.